Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Aerie Pharmaceuticals

Aerie Pharmaceuticals
2005 FOUNDED
PUBLIC STATUS
301-400 EMPLOYEES
AERI STOCK SYMBOL
3 INVESTMENTS
$22.74 SHARE PRICE (As of Friday Closing)
Description

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Its main products are Rhopressa and Roclatan. The company mainly operates in North America.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 4301 Emperor Boulevard
  • Suite 400
  • Durham, NC 27703
  • United States

+1 (919) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Aerie Pharmaceuticals’s full profile, request a free trial.

Aerie Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$17.15 - $50.10 $1.05B $24.11 -$4.33 1.04M 46.3M

Aerie Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 792,321 1,404,922 2,035,543 1,133,346
Revenue 59,687 24,181 0 0
EBITDA (184,707) (231,022) (144,838) (97,896)
Net Income (195,975) (232,569) (145,105) (99,059)
Total Assets 479,208 285,044 290,276 248,254
Total Debt 201,590 0 123,845 123,539
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Aerie Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Aerie Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

Aerie Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Aerie Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Aerie Pharmaceuticals Competitors (26)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Nektar Therapeutics Corporate Backed or Acquired San Francisco, CA 000 00.000 000000000 00.000
000000000 Formerly VC-backed Lexington, MA 00 0000 000000000 0000
000000 Formerly PE-Backed Irvine, CA 000 00000 00000000 00000
00000000 Corporation Austin, TX 00 0000 00000000 0000
0000 0000000000000 Corporate Backed or Acquired Petach Tikva, Israel 00000 00000 00000000000 00000
To view this company’s complete list of competitors, request access »

Aerie Pharmaceuticals Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 000000 13-Dec-2019 000000000000000000 0000 Biotechnology 0000000 00000 00.
0000000 0000000000 05-Oct-2017 000000000 00000 00 0000 Buildings and Property 0000000 00000 00.
Envisia Therapeutics (intellectual property rights ENV1105) 05-Oct-2017 Corporate Asset Purchase 0000 Buildings and Property
To view this company’s complete investment and acquisition history, request access »

Aerie Pharmaceuticals Executive Team (19)

Name Title Board
Seat
Contact
Info
Vicente Anido Jr. Chief Executive Officer & Chairman
Thomas Mitro Chief Operating Officer & President
Richard Rubino Chief Financial Officer & Chief Accounting Officer
Charlene Davis ESQ Chief Compliance Officer & Vice President
Casey Kopczynski Ph.D Chief Scientific Officer

5 Former Executives

You’re viewing 5 of 19 executives. Get the full list »

Aerie Pharmaceuticals Board Members (16)

Name Representing Role Since Contact
Info
Benjamin McGraw III Self Board Member 000 0000
David Gryska Aerie Pharmaceuticals Board Member 000 0000
Geoffrey Duyk Ph.D TPG Biotech Board Member 000 0000
Gerald Cagle Ph.D Self Board Member 000 0000
Julie McHugh Self Board Member 000 0000

8 Former Board Members

You’re viewing 5 of 16 board members. Get the full list »